Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

In an alarming report, Anthropic, an artificial intelligence safety and research company and developer of the Claude family of large language models, said it blocked multiple accounts that used its AI models in ways that could support the development of biological weapons.

In a report published Thursday, the San Francisco-based AI company described biological misuse as one of the “most serious risks” to increasingly capable AI models. The report covers attempts to misuse Claude between December 2025 and August 2026, including activity involving biology, weapons, cyberattacks, influence operations and surveillance.

It details five cases involving potentially concerning biological research, including chikungunya gain-of-function research, avian influenza, orthopoxviruses, venoms and toxins.

“We're publishing our most detailed threat intelligence report to date. It covers how people tried to misuse Claude—for cyberattacks, influence operations, surveillance, biology, and building weapons—and how we found and stopped them,” Anthropic said on X.

What Did Anthropic Find?

Anthropic identified about 35 potentially concerning “research efforts” over 30 days. It could not determine whether users “intended harm” or were conducting legitimate research.

Five cases involved users circumventing safeguards or regional restrictions:

• Chikungunya: AI was used in a gain-of-function project after safeguards were bypassed.
• Avian influenza: AI-assisted planning was used for experiments aimed at adapting the virus to mammals.
• Orthopoxvirus: AI was used to generate a grant application on viral immune evasion.
• Venoms: AI was used to optimise venom-related molecules.
• Toxins: AI was used to computationally redesign toxins.

Anthropic Says It Stopped The Operations

“We disrupted every operation in the report, and used the lessons from them to strengthen our safeguards,” Anthropic said.

The company said it also shared information with authorities and other AI companies where appropriate.

“These cases are not typical: we’re highlighting some of the most sophisticated misuse we’ve seen,” it said.

Can AI Enable Biological Misuse?

The report comes as former Anthropic employee Jacob Coxon resigned this week, stating on X that “the people building AI earnestly believe that it could kill us all by the end of the decade.”

The 27-year-old AI researcher said it could hack critical infrastructure — or build “extinction-level bioweapons.”

“There’s a lot of ways that the AI could actuate itself in the world,” he said. “If you extrapolate into the future, the level of capabilities of these AIs … they could cause extreme havoc,” Coxon later told CNN.

In July, nearly 1,400 AI company employees signed an open letter urging the US government to regulate the technology and slow its development to ensure its safety.

OpenAI Chief Scientist Jakub Pachocki also warned this week that AI capabilities are advancing faster than researchers’ ability to reliably monitor and control them.

Dr Ashish K. Jha, physician, scientist and biosecurity expert, said the Anthropic cases show how AI could lower some barriers to biological research.

“We are sleepwalking into a potentially huge disaster. And it amazes me how little attention it is getting,” Jha said on X.

“Anthropic just published five case studies today of people using Claude in ways that could have helped develop biological weapons. They banned the accounts, traced the networks, and told other AI labs and governments what they found.”

Jha said the barriers that once made biological weapons difficult to develop included “deep expertise, advanced equipment, years of specialized training.” “Those barriers are dissolving. Rapidly,” he said.

Jha also pointed to a case in which Claude blocked a request, after which the operator built a system to route it to a more permissive model.

“In a world of lots of open access models that are getting quite good, this will keep happening,” he said.

The US is seeing a summer surge in COVID-19 infections, with 35 states reporting rising cases, according to the latest update from the Centers for Disease Control and Prevention (CDC).

The September 9 update said cases are declining in eight states and unchanged in seven. COVID-related emergency department visits remain low, while the probability of the epidemic growing is 73%, as per CDC. The cases are expected to grow in the coming weeks.

COVID Activity Rising In US

COVID activity is elevated nationally, but hospitalizations remain low, with the highest rates among infants and adults aged 65 and older.

California, Nevada and Texas have the highest wastewater levels of COVID among US states, according to CDC data.

A south Texas school district reportedly closed for two days in August due to the spread of COVID, citing the need to “protect the health and safety” of students and staff.

Why Is COVID Rising This Summer?

Experts say the summer wave is not unexpected. SARS-CoV-2 spreads year-round but has developed a seasonal pattern in the US.

“We’ve had two waves (every year). One in the middle to late summer, and the other during the winter,” Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center, toldTODAY.com.

“We’re expecting transmission to peak about a week into September,” said Michael Hoerger, assistant professor at Tulane University School of Medicine was also quoted as saying.

With temperatures dropping and children returning to school, opportunities for transmission could increase.

“We need to be very cautious,” Schaffner added.

Which COVID Variants Are Spreading?

WastewaterSCAN data is detecting XFG, LF.7, NB.1.8.1 and BA.3.2. XFG.1.1 and its sublineages accounted for nearly half of US cases in July, according to CDC data. BA.3.2, or Cicada, accounts for less than 10% of cases and has not taken off in the US.

Although there is no new variant, that does not mean COVID-19 cannot cause severe disease, experts noted.

COVID Symptoms 2026

Symptoms remain similar to those caused by other Omicron strains and usually appear two to 14 days after exposure.

Common symptoms include:

• Cough
• Sore throat
• Congestion
• Fatigue
• Fever
• Chills
• Shortness of breath
• Headache
• Nausea and vomiting
• Diarrhea

Many people are reporting an intense sore throat, according to Thomas Russo, professor and chief of infectious diseases at the University at Buffalo in New York.

“Some people feel like it’s the worst sore throat ever, like razor blades in the throat. But it can be more mild in others," he was quoted as saying to Prevention.com

Nausea and diarrhoea can also occur alongside respiratory symptoms.

While for majority COVID will be a flu-like illness, for some it can cause more severe illness like pneumonia and shortness of breath.

Are Vaccines Available?

Adults over 65, infants, people with weakened immune systems or underlying conditions, and those who have never received a COVID vaccine face a higher risk of severe illness or hospitalization, says Schaffner.

In May, the US FDA voted to recommend an updated 2026-2027 COVID vaccine targeting XFG. On August 28, the FDA approved monovalent 2026-2027 COVID vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi.

The updated vaccines are expected to roll out at pharmacies, clinics and hospitals in September.

Obstructive sleep apnea (OSA) affects nearly 1 billion adults worldwide and is linked to cardiovascular disease, stroke and increased mortality.

Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound, which contain tirzepatide, have shown promise in treating sleep apnea in a new review.

While continuous positive airway pressure (CPAP), which uses air pressure to keep the airway open during sleep, remains the standard treatment, some people struggle to use it long term. Adherence rates of 30% to 60% limit its effectiveness at the population level. The review showed that GLP-1 medications may be a potential complementary therapy alongside CPAP.

GLP-1 Drugs And Sleep Apnea

Researchers from the University of Pittsburgh Medical Center, Pennsylvania, reviewed existing evidence on GLP-1 receptor agonists (GLP-1 RAs) for OSA.

Six meta-analyses found consistent reductions in the apnea-hypopnea index (AHI), ranging from 5.7 to 21.9 fewer events per hour.

The Phase 3 SURMOUNT-OSA trials found that tirzepatide reduced AHI by 20 to 24 events per hour compared with placebo. Between 42% and 50% of patients achieved disease remission.

Weight loss is the main established mechanism. GLP-1 RAs may reduce tongue fat and parapharyngel fat, which contribute to airway collapse.

Researchers also identified potential weight-independent effects involving chemosensitivity, leptin pathways and NLRP3 inflammasome suppression, although these mechanisms remain under investigation.

GLP-1 Drugs Vs CPAP

GLP-1 RAs did not match CPAP efficacy, with approximately 22 versus 31 fewer AHI events per hour. Cardiovascular benefits remain unproven, and weight regain commonly occurs after treatment stops.

The researchers said GLP-1 drugs are best positioned as complementary therapy alongside CPAP and other treatments.

The drugs may be appropriate for people with a BMI above 30 who are unable to tolerate CPAP or have obesity-related comorbidities. They are less likely to benefit people without obesity or those with primarily anatomical airway obstruction.

“This review suggests that GLP-1 RAs offer otolaryngologists a disease-modifying adjunct for obesity-related OSA that is best positioned as complementary therapy alongside CPAP, preoperative optimization before upper airway surgery, or potentially to expand hypoglossal nerve stimulator candidacy,” said the researchers in the paper published in JAMA Otolaryngology–Head & Neck Surgery.

What Is Sleep Apnea?

OSA occurs when the airway becomes blocked during sleep, causing breathing to repeatedly stop and restart. These interruptions can occur five to 100 times an hour and can lower oxygen levels and disrupt sleep.

In OSA, the airways become partially or completely blocked when the muscles in the head relax during sleep. This can cause soft tissue to obstruct the windpipe, making it difficult for air to pass through.

While asleep, the chest muscles may work harder than usual to reopen the airway. This can cause jerks, deep gasps and repeated disruptions to sleep.

Symptoms Of Sleep Apnea

Common symptoms include:

• Loud snoring
• Gasping during sleep
• Breathing pauses during sleep
• Morning headaches
• Restless sleep
• Difficulty staying asleep
• Mood changes
• Dizziness
• Dry mouth on waking
• Excessive daytime sleepiness
• Fatigue
• Difficulty concentrating

People may not notice these symptoms themselves, but a partner or family member may observe them.

Can Sleep Apnea Be Prevented?

Measures that may help prevent or manage sleep apnea include:

• Practicing good sleep habits
• Maintaining a healthy weight
• Quitting smoking
• Using CPAP when prescribed
• Avoiding alcohol.